URGN
UroGen Pharma Ltd (URGN)
Healthcare • NASDAQ • $33.70-2.40%
- Symbol
- URGN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $33.70
- Daily Change
- -2.40%
- Market Cap
- $1.69B
- Trailing P/E
- N/A
- Forward P/E
- 13.36
- 52W High
- $50.81
- 52W Low
- $16.37
- Analyst Target
- $60.00
- Dividend Yield
- 0.00%
- Beta
- 1.58
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several for…
Company websiteResearch URGN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.